Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)

Chia-Yau Chang, Jia-Pei Hong, Chian-Her Lee, Shu-Huey Chen, Yen-Lin Liu, Yeu-Chin Chen, Jia-Ruey Tsai, Chen-Hua Tsai, Wan-Ling Ho, Chih-Hong Lee, Jiunn-Horng Kang

Blood (2023) 142 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2023-173113

Published: 2023

Journal Articles

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Jia-Ruey Tsai, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Chao-Neng Cheng, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 3199.

https://doi.org/10.1182/blood-2021-150822

Published: 2021

Journal Articles

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Pei-Yi Lai, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Chao-Neng Cheng, Yen-Lin Liu, Jia-Ruey Tsai, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2021-152066

Published: 2021

Journal Articles

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Jia-Ruey Tsai, Chao-Neng Cheng, Yeu-Chin Chen

Blood (2021) 138 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2021-147069

Published: 2021

Journal Articles

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Chia-Yau Chang, MD, Yeu-Chin Chen, MD, Chen-Hua Tsai, MD, Jia-Ruey Tsai, MD, Yen-Lin Liu, MD, Shu-Hsia Hu

Blood (2019) 134 (Supplement_1): 2406.

https://doi.org/10.1182/blood-2019-132137

Published: 2019

NARROW

The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Email alerts

ASH Publications

American Society of Hematology

The Correlation of Muscle Mass and Walking Distance with Joint Health and Functional Status in Hemophilic Arthropathy Among People with Hemophilia a (PwHA)

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

The Real-World Experience of rFVIII-Fc Used in Hemophilia a Patients in Taiwan: Prophylaxis Rates, Pharmacokinetics and Clinical Correlates, and the Effects on Joint Health

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only